Discounted Cash Flow (DCF) Analysis Levered
CRISPR Therapeutics AG (CRSP)
$71.47
-1.48 (-2.03%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Actual | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected | 2028 Projected |
Revenue | 289.59 | 0.54 | 913.08 | 0.44 | 370 | 234,038.54 | 148,039,618.75 | 93,641,535,913.10 | 59,232,368,486,369.59 | 37,467,064,612,876,600 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | 56.68 | -238.37 | 538.97 | -495.74 | -260.38 | -73,765,769.51 | -46,660,076,629.20 | -29,514,539,948,040.45 | -18,669,237,842,600,004 | -11,809,109,755,299,053,568 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -6.68 | -18.36 | -81.71 | -37.19 | -11.97 | -5,581,726.33 | -3,530,686,116.13 | -2,233,313,443,664.24 | -1,412,668,465,449,417.50 | -893,574,611,721,737,088 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | 49.99 | -256.72 | 457.27 | -532.93 | -272.35 | -79,347,495.84 | -50,190,762,745.33 | -31,747,853,391,704.69 | -20,081,906,308,049,420 | -12,702,684,367,020,789,760 |
Weighted Average Cost Of Capital
Share price | $ 71.47 |
---|---|
Beta | 1.780 |
Diluted Shares Outstanding | 79.22 |
Cost of Debt | |
Tax Rate | -1.92 |
After-tax Cost of Debt | 5.00% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 12.758 |
Total Debt | 238.63 |
Total Equity | 5,661.92 |
Total Capital | 5,900.55 |
Debt Weighting | 4.04 |
Equity Weighting | 95.96 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Actual | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected | 2028 Projected |
Revenue | 289.59 | 0.54 | 913.08 | 0.44 | 370 | 234,038.54 | 148,039,618.75 | 93,641,535,913.10 | 59,232,368,486,369.59 | 37,467,064,612,876,600 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | 56.68 | -238.37 | 538.97 | -495.74 | -260.38 | -73,765,769.51 | -46,660,076,629.20 | -29,514,539,948,040.45 | -18,669,237,842,600,004 | -11,809,109,755,299,053,568 |
Capital Expenditure | -6.68 | -18.36 | -81.71 | -37.19 | -11.97 | -5,581,726.33 | -3,530,686,116.13 | -2,233,313,443,664.24 | -1,412,668,465,449,417.50 | -893,574,611,721,737,088 |
Free Cash Flow | 49.99 | -256.72 | 457.27 | -532.93 | -272.35 | -79,347,495.84 | -50,190,762,745.33 | -31,747,853,391,704.69 | -20,081,906,308,049,420 | -12,702,684,367,020,789,760 |
WACC | ||||||||||
PV LFCF | -70,568,744.08 | -39,699,233,516.13 | -22,333,246,288,652.82 | -12,563,816,618,449,410 | -7,067,915,070,735,883,264 | |||||
SUM PV LFCF | -7,080,501,260,370,423,808 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 12.44 |
Free cash flow (t + 1) | -12,956,738,054,361,206,784 |
Terminal Value | -124,106,686,344,456,011,776 |
Present Value of Terminal Value | -69,054,342,645,120,704,512 |
Intrinsic Value
Enterprise Value | -76,134,843,905,491,124,224 |
---|---|
Net Debt | -150.84 |
Equity Value | -76,134,843,905,491,124,224 |
Shares Outstanding | 79.22 |
Equity Value Per Share | -961,044,561,146,797,056.00 |